Revelation Biosciences has announced that a Phase 2b viral challenge study of its REVTx-99a intranasal phosphorylated hexaacylated disaccharide (PHAD) for the prevention of H3N2 influenza in healthy volunteers failed to meet its primary endpoint. The study, which enrolled 30 subjects aged 18 to 55, failed to demonstrate a statistically significant difference in viral load in the nose between REVTx-99a and placebo, the company said.
In February 2021, Revelation announced that it had raised $4.4 million for development of the nasal drops for the treatment of viral respiratory infections and for possible other indications. The company later said that it would initiate a Phase 1b allergen challenge study of REVTx-99 for the treatment of allergic rhinitis and chronic nasal congestion. According to the new announcement, that study is ongoing, with topline data expected later this year.
Revelation CEO James Rolke commented, “While we are disappointed in the outcome of this study, I would like to thank the study participants, the Revelation team, and the clinical research organization for conducting a well-executed study. We remain committed to the development of our other product candidates including REVTx-99b for management of allergic rhinitis and other underlying conditions; and REVDx-501, our universal at home screening test for respiratory viral infection.”
Read the Revelation Biosciences press release.
